|
ENHANCING ONCOLYTIC VIROTHERAPY WITH TYPE III INTERFERON
|
7R21CA175802-03
|
$171,825
|
$171,825
|
ROBEK, MICHAEL
|
ALBANY MEDICAL COLLEGE
|
|
A New Lab Based Algorithm for HCC Surveillance in Patients with Cirrhosis
|
1R01CA190776-01
|
$666,229
|
$666,229
|
EL-SERAG, HASHEM
|
BAYLOR COLLEGE OF MEDICINE
|
|
Novel targets that are deregulated by loss of PTEN
|
5R01CA108614-09
|
$293,578
|
$293,578
|
JOHNSON, DEBORAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
2P30CA125123-09
|
$3,155,163
|
$126,207
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-09S2
|
$112,151
|
$4,486
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-09S3
|
$183,048
|
$7,322
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Cancer and Leukemia Group B CCOP Research Base
|
3U10CA037447-29S2
|
$334,740
|
$6,695
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-02S1
|
$34,176
|
$1,709
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-02S2
|
$810,357
|
$40,518
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-02
|
$9,967,453
|
$498,373
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Murine Models on SALL4 in Hepatocellular Carcinoma
|
1R03CA184531-01A1
|
$81,724
|
$81,724
|
CHAI, LI
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Selenoproteins as targets for cancer prevention
|
5R01CA080946-15
|
$92,588
|
$92,588
|
GLADYSHEV, VADIM
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Injectable Implants for Increased Tumor Treatment Volume Using Pressure Driven Di
|
1F31CA200373-01
|
$33,337
|
$33,337
|
HERNANDEZ, CHRISTOPHER
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
3U10CA180853-01S1
|
$171,796
|
$4,295
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
5U10CA180853-02
|
$1,360,245
|
$34,006
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
PROHIBITIN 1 IN LIVER INJURY AND CANCER
|
7R01CA172086-02
|
$327,234
|
$327,234
|
LU, SHELLY
|
CEDARS-SINAI MEDICAL CENTER
|
|
The Development of Novel Mechanistically-based APE/Ref-1 Redox Inhibitors
|
7K08CA179084-02
|
$114,468
|
$57,234
|
YANG, SUN
|
CHAPMAN UNIVERSITY
|
|
The Mechanism of Tumor Formation in Beckwith-Wiedemann Syndrome
|
1K08CA193915-01
|
$140,504
|
$140,504
|
KALISH, JENNIFER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Role of Age in Liver Cancer
|
5R01CA159942-05
|
$323,700
|
$323,700
|
TIMCHENKO, NIKOLAI
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
INVESTIGATION OF THE ROLES OF NUCLEAR RECEPTOR FXR IN HEPATOCELLULAR
|
5R01CA139158-05
|
$344,450
|
$344,450
|
HUANG, WENDONG
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-32S1
|
$113,085
|
$2,262
|
ROSEN, STEVEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-32S2
|
$53,400
|
$1,068
|
ROSEN, STEVEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-32S3
|
$50,000
|
$1,000
|
ROSEN, STEVEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-32S4
|
$124,999
|
$2,500
|
ROSEN, STEVEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
5P30CA033572-32
|
$2,184,600
|
$43,692
|
ROSEN, STEVEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cold Spring Harbor Laboratory Cancer Research Center
|
5P01CA013106-44
|
$4,421,268
|
$221,063
|
STILLMAN, BRUCE
|
COLD SPRING HARBOR LABORATORY
|
|
CSHL CANCER CENTER SUPPORT GRANT
|
5P30CA045508-28
|
$4,418,824
|
$88,376
|
STILLMAN, BRUCE
|
COLD SPRING HARBOR LABORATORY
|
|
TLR4 in obesity-driven liver cancer
|
5K22CA178098-03
|
$130,399
|
$130,399
|
CAVIGLIA, JORGE
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-41S1
|
$120,000
|
$2,400
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-41S2
|
$60,000
|
$1,200
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-41S3
|
$125,000
|
$2,500
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-41S4
|
$157,133
|
$3,143
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-41
|
$3,792,720
|
$75,854
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Hepatic Stellate Cells and Liver Cancer
|
1R01CA190844-01
|
$370,197
|
$370,197
|
SCHWABE, ROBERT
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Quantitative Volume and Density Response Assessment: Sarcoma and HCC as a Model
|
5U01CA140207-05
|
$520,335
|
$260,168
|
SCHWARTZ, LAWRENCE
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Myofibroblasts in Gastrointestinal Cancers
|
5U54CA163111-05
|
$501,771
|
$351,240
|
WANG, TIMOTHY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA006516-50S1
|
$122,500
|
$1,225
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-50S2
|
$50,000
|
$500
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-50S3
|
$125,000
|
$1,250
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-50S4
|
$200,000
|
$2,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-50S5
|
$62,500
|
$625
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
5P30CA006516-50
|
$11,162,542
|
$111,625
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
|
5U10CA180867-02
|
$1,171,980
|
$29,300
|
BURSTEIN, HAROLD
|
DANA-FARBER CANCER INST
|
|
Dartmouth Lead Participation in NCI National Clinical Trials Network
|
5U10CA180854-02
|
$319,472
|
$3,993
|
DRAGNEV, KONSTANTIN
|
DARTMOUTH COLLEGE
|
|
Optimization of a clinical stage nanoparticle drug delivery platform
|
1R43CA186410-01A1
|
$184,129
|
$184,129
|
BROWN, BOB
|
DICERNA PHARMACEUTICALS, INC.
|
|
Identification of Altered Glycan and Glycoproteins in Viral Induced Liver Cancer
|
3R01CA120206-09S1
|
$16,465
|
$16,465
|
MEHTA, ANAND
|
DREXEL UNIVERSITY
|
|
Identification of Altered Glycan and Glycoproteins in Viral Induced Liver Cancer
|
3R01CA120206-10S1
|
$15,841
|
$15,841
|
MEHTA, ANAND
|
DREXEL UNIVERSITY
|
|
Identification of Altered Glycan and Glycoproteins in Viral Induced Liver Cancer
|
5R01CA120206-09
|
$469,333
|
$469,333
|
MEHTA, ANAND
|
DREXEL UNIVERSITY
|
|
Aberrantly secreted glycoproteins as markers of liver cancer
|
5U01CA168856-04
|
$336,596
|
$336,596
|
MEHTA, ANAND
|
DREXEL UNIVERSITY
|
|
Identification of Altered Glycan and Glycoproteins in Viral Induced Liver Cancer
|
6R01CA120206-10
|
$55,064
|
$55,064
|
MEHTA, ANAND
|
DREXEL UNIVERSITY
|
Total relevant funding to Liver Cancer for this search: $70,286,751
|